253 results on '"Shillingburg A"'
Search Results
2. Restoration of the Endodontically Treated Tooth
- Author
-
Herbert T. Jr Shillingburg, James C. Kessler and Herbert T. Jr Shillingburg, James C. Kessler
- Published
- 2019
3. Fundamentals of Tooth Preparations for Cast Metal and Porcelain Restorations
- Author
-
Herbert T Shillingburg, Richard Jacobi, Susan E. Brackett and Herbert T Shillingburg, Richard Jacobi, Susan E. Brackett
- Published
- 2019
4. Hematopoietic Progenitor Cell Mobilization with Ifosfamide, Carboplatin, and Etoposide Chemotherapy versus Plerixafor-Based Strategies in Patients with Hodgkin and Non-Hodgkin Lymphoma
- Author
-
Dhakal, Binod, Veltri, Lauren Westfall, Fenske, Timothy S., Eastwood, Daniel, Craig, Michael D., Cumpston, Aaron, Shillingburg, Alexandra, Esselman, Jean, Watkins, Kathy, Pasquini, Marcelo C., D'Souza, Anita, Hari, Parameswaran, Kanate, Abraham Sebastian, and Hamadani, Mehdi
- Published
- 2016
- Full Text
- View/download PDF
5. Hematopoietic progenitor cell mobilization with “just-in-time” plerixafor approach is a cost-effective alternative to routine plerixafor use
- Author
-
Veltri, Lauren, Cumpston, Aaron, Shillingburg, Alexandra, Wen, Sijin, Luo, Jin, Leadmon, Sonia, Watkins, Kathy, Craig, Michael, Hamadani, Mehdi, and Kanate, Abraham S.
- Published
- 2015
- Full Text
- View/download PDF
6. Treatment of severe mucositis pain with oral ketamine mouthwash
- Author
-
Shillingburg, Alexandra, Kanate, Abraham S., Hamadani, Mehdi, Wen, Sijin, Craig, Michael, and Cumpston, Aaron
- Published
- 2017
- Full Text
- View/download PDF
7. Impact of intravenous magnesium infusion rate during ambulatory replacements on serum magnesium concentrations after allogeneic stem cell transplant
- Author
-
Snyder, Matthew, Shillingburg, Alexandra, Newton, Michael, Hamadani, Mehdi, Kanate, Abraham S., Craig, Michael, and Cumpston, Aaron
- Published
- 2016
- Full Text
- View/download PDF
8. Analysis of 14 endocannabinoids and endocannabinoid congeners in human plasma using column switching high-performance atmospheric pressure chemical ionization liquid chromatography–mass spectrometry
- Author
-
Matthew Jackson, Jost Klawitter, Ryan Shillingburg, L. Cinnamon Bidwell, Uwe Christians, Cristina Sempio, Francesca Freni, Kent E. Hutchison, and Jelena Klawitter
- Subjects
Quality Control ,Oleamide ,Atmospheric-pressure chemical ionization ,02 engineering and technology ,Mass spectrometry ,Proof of Concept Study ,01 natural sciences ,Biochemistry ,Mass Spectrometry ,Analytical Chemistry ,chemistry.chemical_compound ,Limit of Detection ,Liquid chromatography–mass spectrometry ,Humans ,Ethanolamide ,Protein precipitation ,Chromatography, High Pressure Liquid ,Cannabis ,Chromatography ,010401 analytical chemistry ,Reproducibility of Results ,021001 nanoscience & nanotechnology ,Endocannabinoid system ,0104 chemical sciences ,Atmospheric Pressure ,chemistry ,0210 nano-technology ,Quantitative analysis (chemistry) ,Endocannabinoids - Abstract
The endocannabinoid system (ECS) is a complex cell-signaling system. To address the growing need of analytics capturing endocannabinoid levels to investigate the ECS, we developed and validated an assay for the quantitative analysis of 14 endocannabinoids and congeners. A simple extraction using protein precipitation with acetonitrile followed by online-trapping high-performance liquid chromatography-tandem mass spectrometry (LC/LC-MS/MS) was used to monitor the levels of 14 endocannabinoids in plasma. The assay was validated and intra-run and inter-run accuracies and imprecisions as well as matrix effects, recoveries, and sample stabilities were determined. As a proof of concept, a subset of study samples after naturalistic administration of Cannabis flower and concentrate was analyzed. With the exception of N-oleoyl dopamine and oleamide, all endocannabinoids fulfilled the predefined acceptance criteria. Reproducible recoveries and no significant matrix effects were observed. Sample stability was an issue. Analysis of the proof-of-concept study samples revealed a significantly (p = 0.006) higher concentration of docosatetraenoyl ethanolamide in concentrate users (300 ± 13 pg/mL) compared to flower users (252 ± 11 pg/mL). A robust, sensitive high-throughput assay for the quantitation of 14 endocannabinoids and congeners was successfully validated. Our study showed that it is mandatory to (A) appropriately stabilize samples and (B) separate and separately quantify 1-AG and 2-AG; otherwise, study results are unreliable. The analysis of study samples from Cannabis flower users versus Cannabis concentrate users revealed higher levels of docosatetraenoyl ethanolamide and anandamide (n.s.) in high THC concentrate users in accordance with the existing literature, supporting the validity of the assay measurements. Graphical abstract.
- Published
- 2021
9. Outcomes of Six-Dose High-Dose Cytarabine as a Salvage Regimen for Patients with Relapsed/Refractory Acute Myeloid Leukemia
- Author
-
Brandi Anders, Lauren Veltri, Abraham S. Kanate, Alexandra Shillingburg, Nilay Shah, Michael Craig, and Aaron Cumpston
- Subjects
Diseases of the blood and blood-forming organs ,RC633-647.5 - Abstract
Relapsed/refractory acute myeloid leukemia (RR-AML) is associated with poor prognosis and long-term disease-free survival requires allogeneic hematopoietic cell transplantation (allo-HCT). Limited data exists, regarding the optimal regimen to obtain remission prior to allo-HCT. Single agent high-dose cytarabine (10–12 doses administered every 12 hours) has been previously used as induction therapy. Six-dose high-dose cytarabine (HiDAC-6), commonly used as a consolidation regimen, has never been evaluated as induction therapy. We present a retrospective review of 26 consecutive patients with RR-AML receiving single agent cytarabine 3 g/m2 intravenously every 12 hours on days 1, 3, and 5 for a total of six doses (HiDAC-6). Median follow-up for surviving patients was 10.4 months (range 1.6–112.2 months). Complete remission was obtained in 62% (54% CR and 8% CRi) of the patients. The median relapse-free survival (RFS) was 22.3 months (range 0.7–112 months), event-free survival (EFS) was 4.7 months (range 0.5–112 months), and the overall survival (OS) was 9.6 months (range 1–112 months). Thirty-five percent of patients were able to subsequently proceed to allo-HCT. Treatment-related toxicities included neutropenic fever (38%), infection (35%), neurotoxicity (8%), and skin toxicity (8%). This is the first study to demonstrate HiDAC-6 as an active treatment option for younger patients with RR-AML which can effectively serve as a bridge to allo-HCT without significant toxicity.
- Published
- 2017
- Full Text
- View/download PDF
10. Fondamenti di protesi fissa: Quarta edizione
- Author
-
Herbert T. Shillingburg and Herbert T. Shillingburg
- Published
- 2014
11. A prospective study of filgrastim pharmacokinetics in morbidly obese patients compared with non-obese controls
- Author
-
Rebecca Moses, Laura F. Gibson, Aaron W. Stewart, Aaron Cumpston, Alexandra Shillingburg, William P. Petros, Debra Piktel, Michael Craig, and Sijin Wen
- Subjects
Adult ,Male ,Neutropenia ,Filgrastim ,business.industry ,Area under the curve ,Cmax ,medicine.disease ,Vial ,Granulocyte colony-stimulating factor ,Obesity, Morbid ,Pharmacokinetics ,Anesthesia ,Case-Control Studies ,Granulocyte Colony-Stimulating Factor ,medicine ,Humans ,Pharmacology (medical) ,Female ,Prospective Studies ,Prospective cohort study ,business ,medicine.drug - Abstract
Introduction Filgrastim is a human granulocyte colony-stimulating factor (G-CSF). There is limited data on dosing filgrastim in obesity. The objective of this study was to compare filgrastim pharmacokinetic parameters for morbidly obese and non-obese patients after a single subcutaneous dose of filgrastim dosed per actual body weight. Methods This prospective, matched-pair study (NCT01719432) included patients ≥18 years of age, receiving filgrastim at 5 mcg/kg with a weight >190% of their ideal body weight (IBW) for "morbidly obese" patients or within 80-124% of IBW for matched control patients. The control group was prospectively matched for age (within 10 years), degree of neutropenia, and gender. Filgrastim doses were not rounded to vial size, to allow more accurate assessment of exposure. Blood samples were collected at 0 (prior to dose), 2, 4, 6, 8, 12, and 24 hours after the first subcutaneous administration of filgrastim. Results A total of 30 patients were enrolled in this prospective pharmacokinetic study, with 15 patients assigned to each arm. Non-compartmental analysis showed that the systemic clearance (Cl) was 0.111 ± 0.041 mL/min in the morbidly obese group versus 0.124 ± 0.045 mL/min in the non-obese group (p=0.44). Additionally, the mean area under the curve (AUC0-24h ) was 49.3 ± 13.9 ng/mL x min in the morbidly obese group versus 46.3 ± 16.8 ng/mL x min in the non-obese group (p=0.6). No differences were seen in maximum concentrations (Cmax ) between the two groups (morbidly obese: 48.1 ± 14.7 ng/mL vs. non-obese: 49.2 ± 20.7 ng/mL (p=0.87)). The morbidly obese group had a numerically higher, but not statistically significant, increase in time to maximum concentration (Tmax ) compared to the non-obese group (544 ± 145 min vs 436 ± 156 min (p=0.06), respectively). Conclusion Calculating subcutaneous filgrastim doses using actual body weight appears to produce similar systemic exposure in morbidly obese and non-obese patients with severe neutropenia.
- Published
- 2021
12. WYSIWYG (what you see is what you get): The Work of Thom Faulders
- Author
-
SHILLINGBURG, DONALD
- Published
- 2007
13. A prospective study of filgrastim pharmacokinetics in morbidly obese patients compared with non‐obese controls
- Author
-
Stewart, Aaron W., primary, Shillingburg, Alexandra, additional, Petros, William, additional, Wen, Sijin, additional, Piktel, Debra, additional, Moses, Rebecca, additional, Gibson, Laura F., additional, Craig, Michael, additional, and Cumpston, Aaron, additional
- Published
- 2021
- Full Text
- View/download PDF
14. Artists on Artists: Don Shillingburg on Beth Campbell
- Author
-
Shillingburg, Don
- Published
- 2005
15. XLA : GOING OFF-SITE: ATOPIA
- Author
-
SHILLINGBURG, DON
- Published
- 2005
16. EXHIBIT TO EXHIBITION: TRACING THE DESIGN OF DILLER + FROM WITHIN THE MUSEUM TO THE MUSEUM
- Author
-
SHILLINGBURG, DON and SCHAFER, ASHLEY
- Published
- 2005
17. Women in oncology pharmacy leadership: A white paper
- Author
-
Jaime Anderson, Alexandra Shillingburg, David W. Henry, Rowena Schwartz, and Laura Boehnke Michaud
- Subjects
Oncology ,medicine.medical_specialty ,Sexism ,education ,Pharmacy ,Pharmacists ,03 medical and health sciences ,0302 clinical medicine ,White paper ,Strategic leadership ,Neoplasms ,Internal medicine ,Health care ,medicine ,Humans ,Pharmacology (medical) ,health care economics and organizations ,geography ,Summit ,geography.geographical_feature_category ,Leadership development ,business.industry ,Call to action ,Leadership ,Pharmaceutical Services ,030220 oncology & carcinogenesis ,Female ,Professional association ,business ,030215 immunology - Abstract
Gender disparity exists in leadership roles within healthcare. While the majority of the healthcare workforce is comprised of women, significantly fewer women occupy leadership positions, particularly at executive and board levels. As the field of oncology pharmacy continues to rapidly expand and evolve, an assessment of the current state of women in oncology pharmacy leadership roles is vital to the growth and development of the profession. In the fall of 2017, the Hematology/Oncology Pharmacy Association (HOPA) hosted a summit to explore leadership issues facing women in oncology pharmacy which have the potential to affect our membership and our profession. This meeting included invited participants from across the fields of oncology and pharmacy and was part of HOPA’s strategic leadership initiative developed through the work of the HOPA Leadership Development Committee in 2016. This promotes a primary goal of HOPA, which is to support oncology pharmacists as they assume leadership roles within their practices and within healthcare to assure oncology pharmacy is integrated into cancer care. The purpose of this white paper is to (1) summarize key issues that were identified through a membership survey; (2) review ongoing efforts to address the needs of female oncology pharmacists in leadership development; (3) serve as a call to action for individuals and professional organizations to assist with and disseminate these efforts and highlight available resources, and (4) to provide practical steps to meet the needs of individuals, training programs, and institutions/employers.
- Published
- 2019
18. Front-line use of tyrosine kinase inhibitors in chronic phase chronic myeloid leukemia: Practice considerations
- Author
-
Hillary Prescott, Julie Kennerly-Shah, Christopher T Elder, Alexandra Shillingburg, Bhavesh Shah, and Michael J Reff
- Subjects
business.industry ,Antineoplastic Agents ,Front line ,Disease ,Protein-Tyrosine Kinases ,Chronic phase chronic myeloid leukemia ,Medical Oncology ,Pharmacists ,Medication Adherence ,03 medical and health sciences ,0302 clinical medicine ,Oncology ,Leukemia, Myelogenous, Chronic, BCR-ABL Positive ,030220 oncology & carcinogenesis ,Cancer research ,Humans ,Medicine ,Drug Interactions ,Pharmacology (medical) ,business ,Protein Kinase Inhibitors ,Tyrosine kinase ,030215 immunology - Abstract
The development of BCR-ABL-targeting tyrosine kinase inhibitors has transformed chronic phase chronic myeloid leukemia (CP CML) from a disease with a terminal prognosis to a treatable chronic illness. Long-term treatment with tyrosine kinase inhibitors means that patients have to be clinically managed and monitored over extended periods of time, thus a patient-centered, medically integrated, and multidisciplinary oncology healthcare team is required to support patients through their journey. Pharmacists work with patients, physicians, and the wider support team to select the optimum therapy plan for a given patient. These decisions are based on risk factors, comorbidities, concomitant medications, and personal circumstances and pharmacists advise on the efficacy and safety of different treatment options. Additionally, pharmacists are a key point-of-contact and resource for monitoring patient response to treatment, identifying and managing adverse events and drug–drug interactions, any subsequent therapy plan modifications, and, potentially, treatment-free remission. Pharmacists also assist with patient education, medication adherence, and financial discussions with patients throughout the long course of the disease. This review provides an overview of BCR-ABL tyrosine kinase inhibitors, discusses the role of the medically integrated pharmacy team, and suggests strategies that pharmacists can use in patient management and clinical decision-making to optimize the treatment of CP CML.
- Published
- 2019
19. Safety and efficacy of aprepitant for chemotherapy-induced nausea and vomiting in pediatric patients: A prospective, observational study
- Author
-
Bodge, Megan, Shillingburg, Alexandra, Paul, Stephan, and Biondo, Lisa
- Published
- 2014
- Full Text
- View/download PDF
20. Impact of Letermovir Prophylaxis on Voriconazole Exposure in Allogeneic Hematopoietic Cell Transplant Recipients
- Author
-
Hamadeh, Issam S., primary, Grunwald, Michael R., additional, Martin, Allison, additional, Patel, Jai N., additional, Shillingburg, Alexandra, additional, Kachur, Ekaterina, additional, COOK, Allene, additional, Karabinos, Allison, additional, Ai, Jing, additional, Knight, Thomas G., additional, Ragon, Brittany K., additional, Chojecki, Aleksander L., additional, Shah, Nilay A., additional, Sanikommu, Srinivasa R., additional, Avalos, Belinda R, additional, Copelan, Edward A, additional, and Shahid, Zainab, additional
- Published
- 2020
- Full Text
- View/download PDF
21. A prospective study of filgrastim pharmacokinetics in morbidly obese patients compared with non‐obese controls.
- Author
-
Stewart, Aaron W., Shillingburg, Alexandra, Petros, William, Wen, Sijin, Piktel, Debra, Moses, Rebecca, Gibson, Laura F., Craig, Michael, and Cumpston, Aaron
- Subjects
- *
FILGRASTIM , *GRANULOCYTE-colony stimulating factor , *OBESITY , *LONGITUDINAL method , *BODY weight , *PHARMACOKINETICS - Abstract
Introduction: Filgrastim is a human granulocyte colony‐stimulating factor (G‐CSF). There are limited data on dosing filgrastim in obesity. The objective of this study was to compare filgrastim pharmacokinetic parameters for morbidly obese and non‐obese patients after a single subcutaneous dose of filgrastim dosed per actual body weight. Methods: This prospective, matched‐pair study (NCT01719432) included patients ≥18 years of age, receiving filgrastim at 5 μg/kg with a weight >190% of their ideal body weight (IBW) for "morbidly obese" patients or within 80%–124% of IBW for matched‐control patients. The control group was prospectively matched for age (within 10 years), degree of neutropenia, and gender. Filgrastim doses were not rounded to vial size, to allow more accurate assessment of exposure. Blood samples were collected at 0 (prior to dose), 2, 4, 6, 8, 12, and 24 h after the first subcutaneous administration of filgrastim. Results: A total of 30 patients were enrolled in this prospective pharmacokinetic study, with 15 patients assigned to each arm. Non‐compartmental analysis showed that the systemic clearance (Cl) was 0.111 ± 0.041 ml/min in the morbidly obese group versus 0.124 ± 0.045 ml/min in the non‐obese group (p = 0.44). Additionally, the mean area under the curve (AUC0‐24h) was 49.3 ± 13.9 ng/ml × min in the morbidly obese group versus 46.3 ± 16.8 ng/mL x min in the non‐obese group (p = 0.6). No differences were seen in maximum concentrations (Cmax) between the two groups (morbidly obese: 48.1 ± 14.7 ng/ml vs. non‐obese: 49.2 ± 20.7 ng/ml (p = 0.87)). The morbidly obese group had a numerically higher, but not statistically significant, increase in time to maximum concentration (Tmax) compared to the non‐obese group (544 ± 145 min vs 436 ± 156 min (p = 0.06), respectively). Conclusion: Calculating subcutaneous filgrastim doses using actual body weight appears to produce similar systemic exposure in morbidly obese and non‐obese patients with severe neutropenia. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
22. Treatment of severe mucositis pain with oral ketamine mouthwash
- Author
-
Alexandra Shillingburg, Aaron Cumpston, Abraham S. Kanate, Michael Craig, Sijin Wen, and Mehdi Hamadani
- Subjects
Adult ,Male ,Mucositis ,Pain medicine ,Mouthwashes ,Pain ,Article ,Young Adult ,03 medical and health sciences ,0302 clinical medicine ,Swallowing ,medicine ,Humans ,Ketamine ,Prospective Studies ,030212 general & internal medicine ,Adverse effect ,Aged ,Stomatitis ,business.industry ,Hematopoietic Stem Cell Transplantation ,Middle Aged ,medicine.disease ,Transplantation ,Oncology ,030220 oncology & carcinogenesis ,Anesthesia ,Adjunctive treatment ,Female ,medicine.symptom ,business ,Odynophagia ,medicine.drug - Abstract
Mucositis is a significant complication of intensive chemotherapy or hematopoietic cell transplantation (HCT), with few treatment options. Ketamine mouthwashes have been used for pain relief, but supporting evidence is limited. The primary objective of this study was to assess the reduction in pain intensity of stomatodynia and odynophagia compared to baseline assessment. This open-label, prospective, phase II interventional study (NCT01566448) was conducted from February 2012 through July 2015. Patients with grade 3 or 4 oral mucositis according to the World Health Organization (WHO) scale as a result of chemotherapy were treated with ketamine mouthwash 20 mg/5 mL four times daily and every 4 h as needed. Thirty patients were enrolled and a total of 136 assessments were conducted. A statistically significant reduction in pain scores of 2 and 3 points was achieved after 1 h and 3 days, respectively (p
- Published
- 2017
23. 'B' v. 'K' plans: a comparison of broadbased plans under Section 403(b) and Section 401(k) after JOPA.
- Author
-
Shillingburg, J. Edward
- Subjects
Salary reduction savings plans -- Laws, regulations and rules ,Nonprofit organizations -- Laws, regulations and rules ,Internal Revenue Code (I.R.C. 403(b)) ,Internal Revenue Code (I.R.C. 401(k)) ,Small Business Job Protection Act of 1996 - Published
- 1997
24. Private foundations and community foundations: major current developments.
- Author
-
Shillingburg, J. Edward
- Subjects
Charitable trusts -- Laws, regulations and rules ,Nonprofit organizations -- Laws, regulations and rules - Published
- 1994
25. Tax issues relating to grants to individuals: the responsibility of charitable organizations and recipients for scholarships, fellowships, prizes and awards.
- Author
-
Shillingburg, J. Edward and Reach, Diane A.
- Subjects
Charitable trusts - Published
- 1993
26. Impact of intravenous magnesium infusion rate during ambulatory replacements on serum magnesium concentrations after allogeneic stem cell transplant
- Author
-
Michael Newton, Matthew Snyder, Alexandra Shillingburg, Michael Craig, Aaron Cumpston, Abraham S. Kanate, and Mehdi Hamadani
- Subjects
Adult ,Male ,medicine.medical_specialty ,Transplantation Conditioning ,medicine.medical_treatment ,Population ,chemistry.chemical_element ,Hematopoietic stem cell transplantation ,030204 cardiovascular system & hematology ,Cohort Studies ,Young Adult ,03 medical and health sciences ,0302 clinical medicine ,medicine ,Humans ,Transplantation, Homologous ,Magnesium ,Infusions, Intravenous ,education ,Aged ,Retrospective Studies ,education.field_of_study ,business.industry ,Hematopoietic Stem Cell Transplantation ,Retrospective cohort study ,Middle Aged ,Surgery ,Calcineurin ,Oncology ,chemistry ,030220 oncology & carcinogenesis ,Anesthesia ,Cohort ,Ambulatory ,Female ,business ,Cohort study - Abstract
For an outpatient cancer center to operate efficiently, optimizing the use of chair time is essential. Allogeneic hematopoietic cell transplant (allo-HCT) recipients are seen frequently in this setting after hospital discharge and regularly for several months thereafter. Aggressive electrolyte replacement is commonly required in these patients, primarily due to renal wasting with calcineurin inhibitor use. Frequent intravenous (IV) magnesium repletion, requiring several hours of infusion time, is often needed in these patients to adequately manage their magnesium deficiencies. The purpose of this study is to explore the impact of extending the infusion rate of intravenous magnesium sulfate on the frequency and degree of IV magnesium replacements required in allo-HCT recipients. We conducted a retrospective study to compare two cohorts of patients administered IV magnesium sulfate at a rate of 4 g/1 h versus 4 g/2 h. A total of 103 continuous patients were assessed in two groups as cohort 1 at the 4 g/1 h rate and cohort 2 at the 4 g/2 h rate. Cohort 1 required less IV magnesium per outpatient visit (median 2.2 vs. 2.9 g/visit, P = 0.0211) and less total IV magnesium replacement through day +100 (median 68 vs. 85 g, P = 0.0479) than cohort 2. These data suggest that there is no apparent benefit of prolonging magnesium infusion from 1 to 2 h in our outpatient allo-HCT population.
- Published
- 2016
27. Oral Antineoplastic Agents: Assessing the Delay in Care
- Author
-
Michael Newton, Brandi Anders, and Alexandra Shillingburg
- Subjects
Receipt ,medicine.medical_specialty ,Article Subject ,business.industry ,Alternative medicine ,Pharmacy ,General Medicine ,Insurance type ,computer.software_genre ,Risk evaluation & mitigation strategies ,Emergency medicine ,Medicine ,Prior authorization ,Data mining ,Patient assistance ,Medical prescription ,business ,computer ,Research Article - Abstract
The study was undertaken to determine the length of time between when a prescription for an oral antineoplastic agent is written by the provider and when the medication is received by the patient and to identify risk factors that significantly increase time to medication receipt. First-time fill prescriptions for oral antineoplastic agents were identified. The date the prescription was written and received by the patient was determined. A retrospective review was completed to gather additional information, including prescribed medication, indication, insurance coverage, patient assistance program use, dispensing pharmacy, and prior authorization requirements. The data was analyzed through multivariate statistical analysis and used to identify risk factors that may significantly increase the time to medication receipt. A total of 58 patients were included in the study. A median of 8 days elapsed between when the medication was prescribed and when it was received by the patient. Medication prescribed, absence of a Risk Evaluation Mitigation Strategies (REMS) program, and insurance type are factors that increased time to medication receipt. An understanding of the median time involved, as well as factors affecting the time to delivery of prescriptions, will help healthcare providers better plan and prepare for the use of oral antineoplastic agents.
- Published
- 2015
28. Front-line use of tyrosine kinase inhibitors in chronic phase chronic myeloid leukemia: Practice considerations
- Author
-
Reff, Michael J, primary, Shillingburg, Alexandra, additional, Shah, Bhavesh, additional, Elder, Christopher, additional, Prescott, Hillary, additional, and Kennerly-Shah, Julie, additional
- Published
- 2019
- Full Text
- View/download PDF
29. Assignment of executive stock options and related developments.
- Author
-
Shillingburg, J. Edward
- Subjects
Employee stock options -- Taxation ,Assignments -- Laws, regulations and rules ,Executives -- Compensation and benefits ,Securities law -- Interpretation and construction - Published
- 1996
30. Entertainment drives retail
- Author
-
Shillingburg, Donald
- Subjects
Shopping centers -- Marketing ,Retail industry -- Marketing ,Architecture and design industries - Abstract
Retail stores and shopping malls are facing a variety of competition, ranging from superstores to video shopping, and are countering by introducing entertainment into their retail plans. Some malls are also offering amenities such as museums, schools and even churches.
- Published
- 1994
31. Evaluation of Serum Posaconazole Concentrations in Patients with Hematological Malignancies Receiving Posaconazole Suspension Compared to the Delayed-Release Tablet Formulation
- Author
-
Nilay A. Shah, Michael Craig, Xiaoxiao Lu, Sijin Wen, Morgan Belling, Aaron Cumpston, Alexandra Shillingburg, and Abraham S. Kanate
- Subjects
0301 basic medicine ,medicine.medical_specialty ,Posaconazole ,Article Subject ,business.industry ,030106 microbiology ,Myeloid leukemia ,Induction chemotherapy ,General Medicine ,Pharmacology ,Gastroenterology ,3. Good health ,Bioavailability ,03 medical and health sciences ,0302 clinical medicine ,Delayed-release tablet ,Internal medicine ,Toxicity ,medicine ,In patient ,030212 general & internal medicine ,Prospective cohort study ,business ,medicine.drug ,Research Article - Abstract
Posaconazole (PCZ) is frequently used for prophylaxis against invasive fungal infections (IFI) in patients undergoing induction chemotherapy for acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). Posaconazole is commercially available as an oral suspension (PCZ-susp) and as a delayed-release tablet (PCZ-tab). Differences in absorption and bioavailability between these formulations may result in variability in serum posaconazole concentrations. The primary objective of this retrospective analysis was to compare attainment of goal serum posaconazole steady state concentrations (Css) ≥ 700 ng/ml in patients with AML/MDS undergoing induction chemotherapy receiving PCZ-susp 600–800 mg per day (N=118) versus PCZ-Tablet 300 mg twice daily for one day, followed by 300 mg daily (N=64). Sixty-two patients (97%) in the PCZ-tab group compared to 20 patients (17%) in the PCZ-susp group achieved goal Css (P<0.0001). Median posaconazole serum Css was 1,665 ng/ml (522–3,830 mg/ml) in the PCZ-tab group versus 390 ng/ml (51–1,870 ng/ml) in the PCZ-susp group (P<0.0001). There was no difference in hepatotoxicity, QTc prolongation, or breakthrough IFI. Patients receiving PCZ-tab were significantly more likely to achieve goal Css and demonstrated higher Css versus patients receiving PCZ-susp. Prospective studies are needed to assess the potential correlation of serum concentrations with efficacy and toxicity.
- Published
- 2017
32. Outcomes of Six-Dose High-Dose Cytarabine as a Salvage Regimen for Patients with Relapsed/Refractory Acute Myeloid Leukemia
- Author
-
Michael Craig, Abraham S. Kanate, Alexandra Shillingburg, Brandi Anders, Aaron Cumpston, Nilay A. Shah, and Lauren Veltri
- Subjects
0301 basic medicine ,medicine.medical_specialty ,Article Subject ,Gastroenterology ,03 medical and health sciences ,0302 clinical medicine ,Refractory ,High dose cytarabine ,Internal medicine ,Medicine ,Diseases of the blood and blood-forming organs ,business.industry ,Myeloid leukemia ,Hematology ,Surgery ,Transplantation ,Regimen ,030104 developmental biology ,030220 oncology & carcinogenesis ,Toxicity ,Relapsed refractory ,Clinical Study ,Cytarabine ,RC633-647.5 ,business ,medicine.drug - Abstract
Relapsed/refractory acute myeloid leukemia (RR-AML) is associated with poor prognosis and long-term disease-free survival requires allogeneic hematopoietic cell transplantation (allo-HCT). Limited data exists, regarding the optimal regimen to obtain remission prior to allo-HCT. Single agent high-dose cytarabine (10–12 doses administered every 12 hours) has been previously used as induction therapy. Six-dose high-dose cytarabine (HiDAC-6), commonly used as a consolidation regimen, has never been evaluated as induction therapy. We present a retrospective review of 26 consecutive patients with RR-AML receiving single agent cytarabine 3 g/m2intravenously every 12 hours on days 1, 3, and 5 for a total of six doses (HiDAC-6). Median follow-up for surviving patients was 10.4 months (range 1.6–112.2 months). Complete remission was obtained in 62% (54% CR and 8% CRi) of the patients. The median relapse-free survival (RFS) was 22.3 months (range 0.7–112 months), event-free survival (EFS) was 4.7 months (range 0.5–112 months), and the overall survival (OS) was 9.6 months (range 1–112 months). Thirty-five percent of patients were able to subsequently proceed to allo-HCT. Treatment-related toxicities included neutropenic fever (38%), infection (35%), neurotoxicity (8%), and skin toxicity (8%). This is the first study to demonstrate HiDAC-6 as an active treatment option for younger patients with RR-AML which can effectively serve as a bridge to allo-HCT without significant toxicity.
- Published
- 2017
- Full Text
- View/download PDF
33. Aprepitant and Fosaprepitant Use in Children and Adolescents at an Academic Medical Center
- Author
-
Lisa Biondo and Alexandra Shillingburg
- Subjects
Pediatrics ,medicine.medical_specialty ,Nausea ,business.industry ,Clinical Investigations ,Electronic medical record ,Fosaprepitant ,Anesthesia ,Chart review ,Pediatrics, Perinatology and Child Health ,medicine ,Vomiting ,Pharmacology (medical) ,medicine.symptom ,business ,Emetogenic chemotherapy ,Highly emetogenic chemotherapy ,Aprepitant ,medicine.drug - Abstract
OBJECTIVE: To describe the use of aprepitant and fosaprepitant, a neurokinin 1 (NK-1) receptor inhibitor, in children and adolescents at a large academic medical center, for the prevention and management of chemotherapy-induced nausea and vomiting (CINV). METHODS: A retrospective chart review was conducted using an electronic medical record system to evaluate the use of aprepitant and fosaprepitant in all pediatric patients that were discharged from a single academic medical center between February 25, 2009 and May 25, 2012. RESULTS: Twenty-six patients were included in this review and received a total of 287 doses over the span of 114 cycles. Mean age was 10.1 years, with a range of 11 months to 17 years old. In 16 of 26 patients, aprepitant was used as the primary prophylaxis. Of those patients who received primary prophylaxis, 6 of 16 received it for highly emetogenic chemotherapy, and 10 of 16 received it for moderately emetogenic chemotherapy. Intravenous fosaprepitant was used in 7 of 26 patients, ages 13 to 17 (median 14) years old. No adverse effects attributable to aprepitant were reported. CONCLUSIONS: Use of aprepitant and fosaprepitant in pediatric patients appeared to be well tolerated. No currently published reports data using aprepitant in a patient younger than 32 months old, whereas we reported its use in patients as young as 11 months old.
- Published
- 2014
34. Front-line use of tyrosine kinase inhibitors in chronic phase chronic myeloid leukemia: Practice considerations.
- Author
-
Reff, Michael J, Shillingburg, Alexandra, Shah, Bhavesh, Elder, Christopher, Prescott, Hillary, and Kennerly-Shah, Julie
- Subjects
- *
PROTEIN-tyrosine kinase inhibitors , *CHRONIC diseases , *QUALITY assurance , *DECISION making in clinical medicine , *OCCUPATIONAL roles , *CHRONIC myeloid leukemia , *MEDICATION therapy management , *THERAPEUTICS - Abstract
The development of BCR-ABL -targeting tyrosine kinase inhibitors has transformed chronic phase chronic myeloid leukemia (CP CML) from a disease with a terminal prognosis to a treatable chronic illness. Long-term treatment with tyrosine kinase inhibitors means that patients have to be clinically managed and monitored over extended periods of time, thus a patient-centered, medically integrated, and multidisciplinary oncology healthcare team is required to support patients through their journey. Pharmacists work with patients, physicians, and the wider support team to select the optimum therapy plan for a given patient. These decisions are based on risk factors, comorbidities, concomitant medications, and personal circumstances and pharmacists advise on the efficacy and safety of different treatment options. Additionally, pharmacists are a key point-of-contact and resource for monitoring patient response to treatment, identifying and managing adverse events and drug–drug interactions, any subsequent therapy plan modifications, and, potentially, treatment-free remission. Pharmacists also assist with patient education, medication adherence, and financial discussions with patients throughout the long course of the disease. This review provides an overview of BCR-ABL tyrosine kinase inhibitors, discusses the role of the medically integrated pharmacy team, and suggests strategies that pharmacists can use in patient management and clinical decision-making to optimize the treatment of CP CML. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
35. Women in oncology pharmacy leadership: A white paper.
- Author
-
Shillingburg, Alexandra, Michaud, Laura B, Schwartz, Rowena, Anderson, Jaime, and Henry, David W
- Subjects
- *
HEALTH facility administration , *HEALTH services administrators , *LABOR mobility , *LEADERSHIP , *ONCOLOGY , *PHARMACOLOGY , *PROFESSIONAL employee training , *SEX discrimination , *WOMEN employees , *OCCUPATIONAL roles - Abstract
Gender disparity exists in leadership roles within healthcare. While the majority of the healthcare workforce is comprised of women, significantly fewer women occupy leadership positions, particularly at executive and board levels. As the field of oncology pharmacy continues to rapidly expand and evolve, an assessment of the current state of women in oncology pharmacy leadership roles is vital to the growth and development of the profession. In the fall of 2017, the Hematology/Oncology Pharmacy Association (HOPA) hosted a summit to explore leadership issues facing women in oncology pharmacy which have the potential to affect our membership and our profession. This meeting included invited participants from across the fields of oncology and pharmacy and was part of HOPA's strategic leadership initiative developed through the work of the HOPA Leadership Development Committee in 2016. This promotes a primary goal of HOPA, which is to support oncology pharmacists as they assume leadership roles within their practices and within healthcare to assure oncology pharmacy is integrated into cancer care. The purpose of this white paper is to (1) summarize key issues that were identified through a membership survey; (2) review ongoing efforts to address the needs of female oncology pharmacists in leadership development; (3) serve as a call to action for individuals and professional organizations to assist with and disseminate these efforts and highlight available resources, and (4) to provide practical steps to meet the needs of individuals, training programs, and institutions/employers. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
36. Hematopoietic Progenitor Cell Mobilization with Ifosfamide, Carboplatin, and Etoposide Chemotherapy versus Plerixafor-Based Strategies in Patients with Hodgkin and Non-Hodgkin Lymphoma
- Author
-
Kathy Watkins, Abraham S. Kanate, Parameswaran Hari, Aaron Cumpston, Binod Dhakal, Michael Craig, Jean Esselman, Lauren Veltri, Alexandra Shillingburg, Marcelo C. Pasquini, Daniel Eastwood, Mehdi Hamadani, Timothy S. Fenske, and Anita D'Souza
- Subjects
Oncology ,Adult ,Male ,medicine.medical_specialty ,Benzylamines ,medicine.medical_treatment ,Antigens, CD34 ,Hematopoietic stem cell transplantation ,Cyclams ,Carboplatin ,03 medical and health sciences ,chemistry.chemical_compound ,Young Adult ,0302 clinical medicine ,Heterocyclic Compounds ,hemic and lymphatic diseases ,Internal medicine ,Antineoplastic Combined Chemotherapy Protocols ,Medicine ,Humans ,Blood Transfusion ,Ifosfamide ,Hematopoietic Stem Cell Mobilization ,Etoposide ,Aged ,Transplantation ,Chemotherapy ,business.industry ,Plerixafor ,Lymphoma, Non-Hodgkin ,Graft Survival ,Hematopoietic Stem Cell Transplantation ,Hematology ,Middle Aged ,medicine.disease ,Hodgkin Disease ,Lymphoma ,Surgery ,chemistry ,030220 oncology & carcinogenesis ,Female ,business ,030215 immunology ,medicine.drug - Abstract
Studies comparing the efficacy and safety of chemo-mobilization with ifosfamide, carboplatin, and etoposide (ICE) ± rituximab with plerixafor-based approaches in lymphoma patients have not been performed. We analyzed hematopoietic progenitor cell mobilization outcomes in lymphoma patients undergoing chemo-mobilization with ICE (n = 35) compared with either routine plerixafor (n = 30) or "just in time" (JIT) plerixafor-based mobilization (n = 33). Chemo-mobilization provided a significantly higher total CD34(+) cell yield (median collection, 5.35 × 10(6) cells/kg for ICE versus 3.15 × 10(6) cells/kg for routine plerixafor and 3.6 × 10(6) cells/kg for JIT plerixafor, P .001). The median day 1 yield of CD34(+) cells was not significantly different (median, 2.2 × 10(6) cells/kg in ICE versus 1.9 × 10(6) cells/kg in upfront plerixafor versus 1.7 × 10(6) cells/kg in JIT plerixafor, P = .20). There was no significant difference in the 3 groups in terms of total number of apheresis sessions performed (median, 2 in each group; P = .78). There were no mobilization failures (inability to collect at least 2 × 10(6) cells/kg) in the chemo-mobilization group, whereas 5 patients (16.7%) in the routine plerixafor and 3 patients (9.1%) in JIT group had mobilization failure (P = .04). Mean time to neutrophil engraftment was faster in the chemo-mobilization group, 10.3 days (±1.2) compared with 12.1 days (±3.6) in the routine plerixafor group and 11.6 days (±3.0) in the JIT group (P .001) and mean time to platelet engraftment was 13.7 days (±.7) in ICE versus 20.3 days (±1.6) in routine plerixafor versus 17.1 days (± .9) in JIT group (P .001). Red blood cell transfusions were significantly higher in the chemo-mobilization group (34.3% versus 0 versus 3.2% versus 1, P .001) and so were the platelet transfusions (22.9% versus 0 versus 0, P .001). Excluding the cost of chemotherapy administration, chemo-mobilization was associated with significantly less mobilization cost (average cost $17,601.76 in ICE versus $28,963.05 in routine and $25,679.81 in JIT, P .001). Our data suggests that chemo-mobilization with ICE provides a higher total CD34(+) cell yield, lower rates of mobilization failure, faster engraftment, and lower cost compared to plerixafor-based approaches with comparable toxicity profile between the groups, except for higher transfusion requirements with chemo-mobilization.
- Published
- 2016
37. Safety and efficacy of aprepitant for chemotherapy-induced nausea and vomiting in pediatric patients: A prospective, observational study
- Author
-
Stephan R. Paul, Lisa Biondo, Megan Bodge, and Alexandra Shillingburg
- Subjects
medicine.medical_specialty ,Activities of daily living ,Nausea ,business.industry ,medicine.drug_class ,Incidence (epidemiology) ,Hematology ,Malignancy ,medicine.disease ,Oncology ,Anesthesia ,Internal medicine ,Pediatrics, Perinatology and Child Health ,medicine ,Antiemetic ,Observational study ,medicine.symptom ,business ,Aprepitant ,Chemotherapy-induced nausea and vomiting ,medicine.drug - Abstract
Pediatric patients between the ages of 12 months and 17 years with a confirmed malignancy who were scheduled to receive aprepitant as part of triple therapy antiemetic prophylaxis for a cycle of moderately- or highly emetogenic chemotherapy were eligible for enrollment. Patients were evaluated for the incidence of nausea, episodes of emesis, interference with activities of daily living (ADLs), and appetite through utilization of a patient survey. Eleven patients were enrolled for a total of 20 patient encounters, mean age 9.55 ± 4.85 (range, 12 months–17 years). Aprepitant was well-tolerated and complete response (CR) rate was 38.9%. Pediatr Blood Cancer 2014;61:1111–1113. © 2013 Wiley Periodicals, Inc.
- Published
- 2013
38. Biomechanical Comparison of Proximal Locking Plates and Blade Plates for the Treatment of Comminuted Subtrochanteric Femoral Fractures
- Author
-
Marjan Nabili, Daniel Shillingburg, Robert V O'Toole, John C P Floyd, Adam H. Hsieh, D. P. Forward, Jason W. Nascone, and Alec Stall
- Subjects
medicine.medical_specialty ,Bone Screws ,Torsion, Mechanical ,Prosthesis Design ,Locking plate ,Weight-Bearing ,Fracture Fixation, Internal ,Fixation (surgical) ,Fracture fixation ,medicine ,Humans ,Minimally Invasive Surgical Procedures ,Orthopedics and Sports Medicine ,Femur ,Fractures, Comminuted ,Orthodontics ,business.industry ,Biomechanics ,food and beverages ,Soft tissue ,General Medicine ,Elasticity ,Internal Fixators ,Biomechanical Phenomena ,Surgery ,Equipment Failure Analysis ,Orthopedic surgery ,Hip Prosthesis ,Stress, Mechanical ,Blade plate ,business ,Bone Plates ,Femoral Fractures - Abstract
The 95 degrees angled blade plate is an accepted standard for plating subtrochanteric femoral fractures but can be technically demanding and often requires extensive soft tissue exposure. Proximal femoral locking plates (PFLPs) have been developed for subtrochanteric and pertrochanteric fractures and are potentially easier to apply with less soft tissue dissection. Clinical experience has raised concerns regarding the strength of the PFLP. The purpose of our study was to compare the relative stability of two designs of PFLP with the 95 degrees angled blade plate under loads simulating the first 3 months of progressive weight bearing after fracture fixation.A comminuted subtrochanteric femoral fracture model was created with a 2-cm gap below the lesser trochanter in 15 synthetic femora. Fracture fixation of three plates (95 degrees angled blade plate [blade plate], the original version of the PFLP [O-PFLP], and the newest version of the PFLP [N-PFLP]), all manufactured by Synthes, Inc., Paoli, PA, was tested under progressive cyclic loading to reproduce progressive weight bearing during 3 months after fracture fixation. The force and number of cycles to reach 5 mm of displacement of the femoral head or failure of the implant were compared for each implant.N-PFLPs were significantly stiffer than blade plates and O-PFLPs (P = 0.01) and had a trend toward withstanding more cycles before failure (P = 0.06). All five O-PFLPs demonstrated catastrophic fatigue failure before completion of the protocol. One each of the blade plates and the N-PFLPs failed to complete the protocol (P = 0.04).In the model studied, N-PFLPs were shown to have biomechanical properties that were at least equivalent to those of the blade plate. The fatigue failures of O-PFLPs mirrored our clinical experience. Use of the N-PFLP might be a viable alternative fixation method for comminuted subtrochanteric femoral fractures that currently are treated with blade plates.
- Published
- 2009
39. Evaluation of Serum Posaconazole Concentrations in Patients with Hematological Malignancies Receiving Posaconazole Suspension Compared to the Delayed-Release Tablet Formulation
- Author
-
Belling, Morgan, primary, Kanate, Abraham S., additional, Shillingburg, Alexandra, additional, Lu, Xiaoxiao, additional, Wen, Sijin, additional, Shah, Nilay, additional, Craig, Michael, additional, and Cumpston, Aaron, additional
- Published
- 2017
- Full Text
- View/download PDF
40. Outcomes of Six-Dose High-Dose Cytarabine as a Salvage Regimen for Patients with Relapsed/Refractory Acute Myeloid Leukemia
- Author
-
Anders, Brandi, primary, Veltri, Lauren, additional, Kanate, Abraham S., additional, Shillingburg, Alexandra, additional, Shah, Nilay, additional, Craig, Michael, additional, and Cumpston, Aaron, additional
- Published
- 2017
- Full Text
- View/download PDF
41. Superior Serum Concentrations with Posaconazole Delayed-Release Tablets Compared to Suspension Formulation in Hematological Malignancies
- Author
-
Alexandra Shillingburg, Xiaoxiao Lu, Mehdi Hamadani, Michael Craig, Sijin Wen, Aaron Cumpston, Abraham S. Kanate, and Ryan James Caddell
- Subjects
Adult ,Male ,medicine.medical_specialty ,Posaconazole ,Antifungal Agents ,Adolescent ,Chemistry, Pharmaceutical ,Clinical Therapeutics ,QT interval ,Gastroenterology ,Young Adult ,Suspensions ,Internal medicine ,medicine ,Humans ,Pharmacology (medical) ,In patient ,Interval prolongation ,Antibiotic prophylaxis ,Adverse effect ,Aged ,Pharmacology ,Aged, 80 and over ,business.industry ,Serum concentration ,Antibiotic Prophylaxis ,Middle Aged ,Triazoles ,Infectious Diseases ,Mycoses ,Anesthesia ,Delayed-Action Preparations ,Hematologic Neoplasms ,Toxicity ,Female ,business ,medicine.drug ,Tablets - Abstract
Posaconazole (PCZ), approved for prophylaxis against invasive fungal disease in high-risk patients, is commercially available orally as a suspension formulation (PCZ-susp) and as a delayed-release tablet (PCZ-tab). We evaluated the serum steady-state concentrations ( C ss ) of PCZ stratified by the administered formulation for antifungal prophylaxis in patients with myeloid malignancies ( n = 150). The primary outcome was the attainment rate of the target C ss of ≥700 ng/ml. Secondary outcomes included toxicity assessment (hepatotoxicity and corrected QT [QTc] interval prolongation) and breakthrough fungal infections. Patients who received the PCZ-susp ( n = 118) or PCZ-tab ( n = 32) and had PCZ C ss assessment after at least 7 days of therapy were eligible. The median C ss in the PCZ-susp group was 390 ng/ml (range, 51 to 1,870 ng/ml; mean, 436 ng/ml) compared to 1,740 ng/ml (range, 662 to 3,350 ng/ml; mean, 1,781 ng/ml) in the PCZ-tab group ( P < 0.0001). The percentages of patients achieving the target goal of ≥700 ng/ml were 17% versus 97%, respectively ( P < 0.0001). Hepatotoxicity (grade 2 or higher) occurred in 1 patient in each group. QTc interval measurements were available for 32 patients in the PCZ-susp group and for 12 patients in the PCZ-tab group, and prolonged intervals of grade 2 or higher were noted in 9% ( n = 3) and 17% ( n = 2), respectively ( P = 0.6). Breakthrough fungal infections in the PCZ-susp and PCZ-tab groups were 7% ( n = 8) and 3% ( n = 1), respectively ( P = 0.68). We conclude that the use of PCZ-tab was associated with higher C ss and with the probability of achieving therapeutic goals without worsening of adverse effects.
- Published
- 2015
42. Drug-induced immune hemolytic anemia associated with albumin-bound paclitaxel
- Author
-
Alexandra Shillingburg and Roby Antony Thomas
- Subjects
Drug ,business.industry ,Anemia ,media_common.quotation_subject ,Hematology ,Hypoglycemia ,medicine.disease ,Hemolysis ,Immune Hemolytic Anemia ,chemistry.chemical_compound ,Immune system ,Oncology ,Albumin bound paclitaxel ,Paclitaxel ,chemistry ,Immunology ,Medicine ,business ,media_common - Abstract
Drug-induced immune hemolytic anemia (DIIHA) is rare, with only 1 patient in 1 million affected by the condition.1 Garratty identified 125 drugs indicated in DIIHA of which 11% were antineoplastic agents, and neither paclitaxel nor albumin-bound paclitaxel were included.2 In addition, we did not find any reports in our own search of the literature. Taxanes are known to cause anemia as a result of their myelosuppressive effects, but an immune hemolysis is rare. To our knowledge, we present here the first case of DIIHA with nab-paclitaxel.
- Published
- 2014
43. Comparison of the bond strength of resin-bonded retainers using two metal etching techniques.
- Author
-
El-Sherif, Moustafa H., Shillingburg, Jr., Herbert T., and Duncanson, Jr., Manville G.
- Subjects
DENTAL bonding ,DENTAL acid etching ,DENTAL caries ,BICUSPIDS ,MAXILLA ,DENTAL resins ,STANDARD deviations ,STATISTICS ,DENTAL abutments - Abstract
The article focuses on a study which compares the bond strength produced by two metal etching techniques, the acid-gel technique and the electrochemical-etching technique. 20 caries-free maxillary human premolars were selected, cleaned and embedded in autopolymerizing resin. A wax pattern was fabricated for each specimen and the specimens were divided randomly into two groups for the two etching techniques. The mean values and standard deviations of the bonding strengths of the resin-bonded retainers were calculated. The results show high standard deviations and offer supportive data for use of the acid-gel method. It concludes that the acid-gel etching is capable of creating a stronger bond between acid-etched, resin-bonded retainers and abutment teeth than electrochemical etching.
- Published
- 1989
44. Radiopacity and color of elastomeric impression materials.
- Author
-
Shillingburg, Jr., Herbert T., Case, Jay C., Duncanson, Jr., Manville G., and Kent, William A.
- Subjects
DENTAL research ,OPERATIVE dentistry ,ELASTOMERS in dentistry ,DENTAL impressions ,DENTAL impression materials ,DENTAL materials ,DENTAL therapeutics ,DENTAL pathology ,HYDROCOLLOIDS - Abstract
The article presents the results of a study about radiocapacity and color of elastomeric impression materials used in dentistry. A step-wedge configuration was used for the experiment and the model was duplicated using reversible hydrocolloid material and a refractory investment. The data collected for each impression material by brand, viscosity and chemical classification, consisted of densitometer values for six thickness of each impression materials, the chart of which is presented. The conclusions that were drawn from this experiment were that impression materials in easily seen contrasting colors should be used to minimize the possibility of missing tags which may be left behind.
- Published
- 1988
45. Taper of clinical preparations for cast restorations.
- Author
-
Kent, William A., Shillingburg, Jr., Herbert T., and Duncanson, Jr., Manville G.
- Subjects
DIASTEMA (Teeth) ,DENTAL casting ,DENTAL therapeutics ,PROSTHODONTICS ,DENTAL occlusion ,PROSTHETICS ,TOOTH care & hygiene ,DENTAL research ,DENTAL care - Abstract
The article offers information on a study conducted in order to determine the degree of taper of tooth preparation. In a tooth preparation, taper is the relationship between two opposite and converging or diverging vertical surfaces of tooth structure. The research has revealed that the more widely separated the walls being prepared, the greater is the taper. Features such as grooves and boxes that are added to clinical preparations have less taper as compared to axial walls of the overall tooth preparations.
- Published
- 1988
46. Fluid Control for Cast Restorations.
- Author
-
Shillingburg, Jr., Herbert T., Hobo, Sumiya, and Whitsett, Lowell D.
- Subjects
DENTAL casting ,DENTAL technology ,OPERATIVE dentistry ,ENDODONTICS ,TONGUE ,DENTAL equipment ,DENTAL caries ,DENTISTRY ,DENTAL therapeutics - Abstract
The article discusses the issue of fluid control for cast restorations in restorative endodontics. In restorations, the need for removal of fluids depend upon the task being performed and in preparation of teeth, it is necessary to remove large volumes of water produced by the handpiece spray and to control the tongue to prevent accidental injury. Rubber dam is reported to be the most effective isolation device used, valued in the removal of old restorations or excavation of caries. High volume vacuum is another device which is reported to be extremely useful during the preparation phase and is most effectively used with an assistant.
- Published
- 1982
47. Restoration of Crowned Teeth After Endodontic Treatment.
- Author
-
Shillingburg. Jr, Herbert T. and Kessler, James C.
- Subjects
DENTAL casting ,DOWELS ,INLAYS (Dentistry) ,ENDODONTICS ,DENTAL cements ,GOLD alloys ,SILICON carbide ,DENTAL crowns ,DENTAL pulp cavities - Abstract
The article discusses the process of dowels casting along with an inlay to solve the problem of endodontic access through a crown. Dentists term the combination of a dowel and an inlay as dowel-inlay and refers the repair process as a secondary intention dowel. Under this technique, the mouth of the canal is first extended enough to remove any undercuts and particularly toward the facial wall of the preparation. An impression, as stated, is then made of the finished dowel preparation using any light bodied elastomeric injection material, and then the wall of the dowel preparation is coated with Lentulo spiral cement fillers. Dentists state that for a good marginal fit, gold alloy is used for casting a dowel-inlay and a carborundum stone is used to blend the contour of the dowel-inlay.
- Published
- 1982
48. Rationale for occlusal morphology in cast restorations.
- Author
-
Shillingburg Jr., Herbert T., Wilson Jr., Edwin L., and Morrison, Jack T.
- Subjects
LITERARY excerpts - Abstract
An excerpt from the book "Guide to Occlusal Waxing," by Herbert T. Sillingburg, Edwin L. Wilson and Jack T. Morrison is presented.
- Published
- 1979
49. Wettability of Elastomeric Impression Materials: Effect of Selected Surfactants.
- Author
-
McCormick, Jeffrey T., Antony, Susan J., Dial, Michael L., Duncanson, Jr., Manville G., and Shillingburg, Jr., Herbert T.
- Subjects
HYDROCOLLOIDS ,BACTERIAL cell surfaces ,HYDROPHOBIC surfaces ,SURFACE active agents ,POLYETHERS ,SILICONES in medicine ,MEDICAL polymers ,DENTAL materials ,COLLOIDS - Abstract
This study evaluated seven classes of 65 impression materials for the effect of selected surfactants on contact angle values for high-strength stone. Uniform surfaces of the materials were treated with a surfactant, and stone samples were poured on each impression material surface. The samples were sectioned and photographed for measurement of the advancing contact angles. Statistical analysis supported four conclusions: No significant difference was found between the two surfactants. Both surfactants were significantly better than the control (water). Polyether impression materials were superior in wettability to the other elastomeric impression materials tested. With respect to contact angle, two distinct groups of impression materials emerged. Reversible hydrocolloid (47.7 ± 1.5), irreversible hydrocolloid (36.8 ± 8.8), and polyether (45.8 ± 7.6) formed a hydrophilic group. A hydrophobic group consisted of the polysulfide (62.6 ± 10.1), poly(vinyl siloxane) (71.1 ± 12.3), condensation-reaction silicone (74.1 ± 11 .0), and polyethene (75.9 ± 14.6) materials. [ABSTRACT FROM AUTHOR]
- Published
- 1989
50. Effect of luting media on the compressive strengths of two types of all-ceramic crown.
- Author
-
McCormick, Jeffrey T., Rowland, Wade, Shillingburg Jr., Herbert T., and Duncanson Jr., Manville G.
- Subjects
DENTISTRY ,CERAMIC coating ,DENTAL ceramics ,ZINC phosphide ,IONOMERS ,DENTAL resins - Abstract
This study evaluated the effect of selected luting media on the compressive strengths of two types of all ceramic crown. Tooth preparation was standardized; each preparation had a shoulder width of approximately 1.2 mm, and all internal preparation angles were rounded. Hi-Ceram and Dicor all-ceramic crowns were fabricated and cemented into the preparations with zinc phosphate, glass-ionomer, or composite resin cement. Coronal compressive fracture strengths were determined, using a set of unrestored teeth as a control. There were no statistically significant differences among the mean compressive strengths of the three luting media, and there was no statistically significant difference between the mean compressive strength of Dicor and that of the natural tooth control. [ABSTRACT FROM AUTHOR]
- Published
- 1993
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.